Search research articles
Contact Us
Filters
Showing results (201-210 of 241) with videos related to
Page
of 25
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2009
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial
James C Yao, Catherine Lombard-Bohas, Eric Baudin, et al.
Neuroendocrinology
|
August 17, 2017
Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study
Francesca Marciello, Olaf Mercier, Piero Ferolla, et al.
The Lancet. Oncology
|
October 28, 2017
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
Piero Ferolla, Maria Pia Brizzi, Tim Meyer, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 5, 2022
Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France
Alexandre Dormoy, Magalie Haissaguerre, Géraldine Vitellius, et al.
Endocrine-Related Cancer
|
August 3, 2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study
Julien Hadoux, Thomas Walter, Christina Kanaan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 13, 2020
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Cancer
|
June 23, 2022
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies
Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
European Journal of Endocrinology
|
December 25, 2014
Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'étude des Tumeurs Endocrines (GTE) retrospective study
Delphine Vezzosi, Catherine Cardot-Bauters, Nicolas Bouscaren, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 6, 2025
Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks
Sarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, et al.
Lancet (London, England)
|
February 25, 2024
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
Eric Baudin, Bernard Goichot, Alfredo Berruti, et al.
Page
of 25
Search research articles
Search
Showing results (201-210 of 241) with videos related to
Sort By:
Page
of 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2009
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial
James C Yao, Catherine Lombard-Bohas, Eric Baudin, et al.
Neuroendocrinology
|
August 17, 2017
Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study
Francesca Marciello, Olaf Mercier, Piero Ferolla, et al.
The Lancet. Oncology
|
October 28, 2017
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
Piero Ferolla, Maria Pia Brizzi, Tim Meyer, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 5, 2022
Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France
Alexandre Dormoy, Magalie Haissaguerre, Géraldine Vitellius, et al.
Endocrine-Related Cancer
|
August 3, 2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study
Julien Hadoux, Thomas Walter, Christina Kanaan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 13, 2020
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Cancer
|
June 23, 2022
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies
Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
European Journal of Endocrinology
|
December 25, 2014
Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'étude des Tumeurs Endocrines (GTE) retrospective study
Delphine Vezzosi, Catherine Cardot-Bauters, Nicolas Bouscaren, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 6, 2025
Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks
Sarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, et al.
Lancet (London, England)
|
February 25, 2024
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
Eric Baudin, Bernard Goichot, Alfredo Berruti, et al.
Page
of 25